Streetbeat News

ELEV

Elevation Oncology, Inc.

Industry

Biotechnology

Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.

Open

0.60

Mkt cap

36M

Volume

481K

High

0.62

P/E Ratio

-0.76

52-wk high

5.83

Low

0.57

Div yield

N/A

52-wk low

0.44

Elevation Oncology reported its Q3 2024 financial results, highlighting promising Phase 1 data for EO-3021 with a 42.8% ORR in a specific cancer subset. The company is progressing with trials and plans to present further data in 2024.

Portfolio Pulse from

November 06, 2024 | 12:45 pm

The Biden-Harris Administration has proposed a Medicare $2 Drug List Model aimed at reducing prescription costs. The Centers for Medicare & Medicaid Services (CMS) is seeking feedback on a sample drug list and plans to start voluntary participation for Part D sponsors as early as January 2027. The model will include drugs for common conditions and will be updated periodically based on new generics, clinical indications, and pricing trends.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 12:57 pm

Several healthcare stocks experienced significant price movements in Friday's after-market session. Notable gainers included IGC Pharma, TC BioPharm, and OptiNose, while Gain Therapeutics, Estrella Immunopharma, and Eyenovia were among the losers.

Portfolio Pulse from Benzinga Insights

September 27, 2024 | 8:31 pm

Elevation Oncology's EO-3021 has received FDA Fast Track designation for treating advanced gastric cancer, highlighting its potential to address unmet medical needs. The designation is based on promising early clinical trial results.

Portfolio Pulse from Benzinga Newsdesk

September 23, 2024 | 11:36 am

HC Wainwright & Co. analyst Swayampakula Ramakanth has reiterated a Buy rating on Elevation Oncology (NASDAQ:ELEV) and maintained a $6 price target.

Portfolio Pulse from Benzinga Newsdesk

August 07, 2024 | 8:13 pm

The S&P 500 surged over 2% on Tuesday, driven by strong earnings reports from companies like Caterpillar Inc. (CAT), which beat earnings estimates. Other notable stock movements included significant gains for TG Therapeutics (TGTX), Clear Secure (YOU), and Lumen Technologies (LUMN), while Elevation Oncology (ELEV), Jumia Technologies (JMIA), and ThredUp (TDUP) saw substantial declines.

Portfolio Pulse from Avi Kapoor

August 06, 2024 | 6:39 pm

Elevation Oncology Inc. (NASDAQ:ELEV) stock is trading lower after reporting initial data from its Phase 1 trial of EO-3021. The trial showed mixed efficacy results, with a 42.8% objective response rate in patients with high Claudin 18.2 expression. The company plans to continue the trial and expects to share more data in 2025. ELEV stock is down 59% to $0.8733.

Portfolio Pulse from Vandana Singh

August 06, 2024 | 4:36 pm

U.S. stocks traded higher with the Nasdaq Composite gaining over 250 points. Yum! Brands reported better-than-expected earnings, while TG Therapeutics, Clear Secure, and Lumen Technologies saw significant stock price increases. Elevation Oncology, Jumia Technologies, and ThredUp experienced substantial declines.

Portfolio Pulse from Avi Kapoor

August 06, 2024 | 4:05 pm

U.S. stocks traded higher with the Dow Jones index gaining over 300 points. The trade deficit in the U.S. narrowed to $73.1 billion in June. VBI Vaccines, Regencell Bioscience, and Lumen Technologies saw significant stock price increases, while Elevation Oncology, Jumia Technologies, and ThredUp experienced notable declines.

Portfolio Pulse from Avi Kapoor

August 06, 2024 | 2:22 pm

Elevation Oncology announced that its existing cash, cash equivalents, and marketable securities totaling $110.8 million as of June 30, 2024, are expected to be sufficient to fund its current operations into 2026.

Portfolio Pulse from Benzinga Newsdesk

August 06, 2024 | 11:25 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.